Related Experiment Videos
The antiparkinsonian activity of CQA 206-291, a new D2 dopamine receptor agonist
J A Temlett1, N P Quinn, C D Marsden
1University Department of Clinical Neurology, National Hospital for Nervous Diseases, London, England.
Clinical Neuropharmacology
|February 1, 1989
Abstract:
CQA 206-291, a new D2 dopamine receptor agonist with a biphasic dopaminergic profile, was given to six patients with idiopathic Parkinson's disease after overnight drug withdrawal. With incremental single oral doses of CQA, a dose-related, clinically significant, and prolonged antiparkinsonian effect was observed. Most subjects experienced drowsiness after the drug while a minority of subjects experienced nausea and/or vomiting or postural hypotension. Further study of this drug in humans is indicated.